

## FREEDOM OF INFORMATION REQUEST

RF23-425

### Request:

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- Lonsurf (Trifluridine - tipiracil)
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- Nivolumab monotherapy or combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:

- Nivolumab monotherapy or combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only



Q4. In the past 3 months, how many patients have been initiated\* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:

- Nivolumab monotherapy or in combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q5. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.

Q6. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.

**Response:**

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested.

1.

CAPOX (Capecitabine with Oxaliplatin)	6
FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)	<5*
Lonsurf (Trifluridine - tipiracil)	0
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<5*
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
Any other systemic anti-cancer therapy	13
Palliative care only	Unknown**

2.

Nivolumab monotherapy or combination with Ipilimumab	5
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<5*
Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)	24
Any other systemic anti-cancer therapy	21
Palliative care only	Unknown**



3.

Nivolumab monotherapy or combination with Ipilimumab	<b>&lt;5*</b>
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)	<b>0</b>
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)	<b>&lt;5</b>
Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)	<b>17</b>
Any other systemic anti-cancer therapy	<b>7</b>
Palliative care only	<b>Unknown**</b>

4.

Nivolumab monotherapy or in combination with Ipilimumab	<b>&lt;5*</b>
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)	<b>0</b>
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)	<b>0</b>

5. Gastric Cancer Study: ADD ASPIRIN – IRAS No: 120104 – <5\* patients in follow up

6. Oesophageal Cancer Study: SCOPE2 – IRAS No: 169633 – <5\* patients in follow up

\* EKHUFT is unable to confirm the exact number where fewer than five patients are recorded. Given the low number, we consider that disclosure of such information, which constitutes personal data, would contravene the first data protection principle under GDPR. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle, which in our view, would be breached by disclosure. We believe that not disclosing this information is in line with Sections 40(2) and 40(3) of the Freedom of Information Act 2000.

\*\*EKHUFT regret we are unable to answer this question as this data is not recorded in ARIA e-prescribing pharmacy system.

**(DATE OF RESPONSE: 17 JULY 2023)**

